472
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Treatment and outcome patterns of patients with Waldenström’s macroglobulinemia: a large, multicenter retrospective review in China

ORCID Icon, , , , , , , , , , , , ORCID Icon, , , , , , , , , , , , , , , , , , , , , , ORCID Icon, ORCID Icon & show all
Pages 2657-2664 | Received 12 Apr 2021, Accepted 26 May 2021, Published online: 09 Jun 2021

References

  • Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30(2):110–115.
  • Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer. 2012;118(15):3793–3800.
  • Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenstrom’s macroglobulinemia. Blood. 2016;128(10):1321–1328.
  • Rourke M, Anderson KC, Ghobrial IM. Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma. 2010;51(10):1779–1792.
  • Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma,or lymphoplasmacytic lymphoma. J Clin Oncol. 2013;31(3):301–307.
  • Oza A, Rajkumar SV. Waldenstrom macroglobulinemia: prognosis and management. Blood Cancer J. 2015;5(3):e394–e394.
  • Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. N Engl J Med. 2018;378(25):2399–2410.
  • Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163–4170.
  • Kastritis E, Morel P, Duhamel A, et al. A revised international prognostic score system for Waldenström’s macroglobulinemia. Leukemia. 2019;33(11):2654–2661.
  • Shuhua Y, Rui C, Zengjun L, et al. Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenström macroglobulinemia. Chin Med J (Engl). 2014;127:2327–2331.
  • Cao XX, Meng Q, Cai H, et al. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease. Ann Hematol. 2017;96(6):971–976.
  • Iwanaga M, Chiang CJ, Soda M, et al. Incidence of lymphoplasmacytic lymphoma/Waldenström’s macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996–2003. Int J Cancer. 2014;134(1):174–180.
  • Brandefors L, Melin B, Lindh J, et al. Prognostic factors and primary treatment for Waldenstro€m macroglobulinemia – a Swedish Lymphoma Registry study. Br J Haematol. 2018;183(4):564–577.
  • Kristinsson SY, Bjo€Rkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasma- cytic lymphoma/Waldenstro€m macroglobuline- mia patients: a population-based study in Sweden. Blood. 2008;112(8):3052–3056.
  • Buske C, Sadullah S, Kastritis E, et al. Treatment and outcome patterns in European patients with Waldenström’s macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018;5(7):e299–e309.
  • Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009;23(1):153–161.
  • Treon SP, Meid K, Gustine J, et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstro ¨m macroglobulinemia. J Clin Oncol. 2021;39(6):565–575.
  • Morel P, Monconduit M, Jacomy D, et al. Patients with the description of a new scoring system and its validation on 253 other patients. Blood. 2000;96(3):852–858.
  • Treon SP. How I treat Waldenstro€m macroglobulinemia. Blood. 2015;126(6):721–732.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.